Skip to content
★ Sign in to follow
TS

Tofflon Science and Technology Group Co., Ltd. Stock: price and insider trades · China

东富龙

CN·Mcap CN¥10.6BHealth Care

No insider purchase over the last 90 days. The latest, by 郑效东, was filed 29 Dec 2023.

Tofflon Science and Technology Group Co., Ltd.: what insiders have been doing

This page follows insider dealings at Tofflon Science and Technology Group Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. The past year has been quiet: not a single insider filing for Tofflon Science and Technology Group Co., Ltd. The previous disclosure was published on 29 December 2023.

Since 2021, the database holds 1 purchase and 1 sale by insiders of the company.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.

Insider Decl.
2
Thresholds
n/a
Buy Volume
€527,437
1 ops. · all time
Sell Volume
€266,924
1 ops. · all time

Since the insiders bought

  • Filed 29 Dec 2023 · 1045 days ago · €527k
    -22.7%
    Entry CN¥17.88 · Close at T+365 CN¥13.83

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate Tofflon Science and Technology Group Co., Ltd. Buy (bullish), based on 2 analysts. Average price target: CN¥18.75.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 15,549 of 26,911 companies
46.9
score / 100
Value
40
Quality
54
FCF yld4.3%
Earn yld1.9%
EV/EBITDA25.4x
ROE3.6%
Gross mgn29%
Net mgn3.8%
Debt/EBITDA0.2x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥13.84
Analyst consensus
2 analysts
Buy
CN¥16.50Target CN¥18.75(+35%)CN¥21.00
Income statement
RevenueCN¥5.2B
Gross profitCN¥1.5B29% margin
EBITDACN¥420.3M8% margin
Net incomeCN¥200.4M4.9% margin
Valuation
PER (trailing)40.7x
PER (forward)19.2x
P/Book1.3x
Beta0.28
Balance sheet & cash
Market capCN¥10.6B
Total debtCN¥88.2M
Free Cash FlowCN¥459.6M
Debt / Equity1%
Profitability & ownership
ROE3.6%
ROA1.5%
% insiders53.0%
% institutions11.5%
Last declaration on 29 December 2023
Declarations2 total
  • ▲
    董事,高管Executives
    4M CNY15SZSE
    230,000 shares100.0% of flowA股XSHESZSE:173000007201482750
    Canonical exit: 28 Mar 2024 (T+90)
  • ▼
    董事,高管Executives
    2M CNY15SZSE
    52,000 shares100.0% of flowA股XSHESZSE:173000006638602460

2 of 2 declarations

About Tofflon Science and Technology Group Co., Ltd.

东富龙 is a company in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the development and manufacturing of innovative pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations